NEW YORK, March 23 – Aurora Biosciences said it has hired William Ettouati, former co-CEO of Geneva Proteomics, as vice president of business development.

Ettouati, who was at the helm of Geneva Proteomics from April to August of last year, will seek to expand Aurora’s business in Europe and develop other strategic alliances, Aurora said. Before his term at GeneProt, Ettouati headed up Ceptyr, a Seattle-based biotech company developing PTP-based therapeutics. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.